L&C Bio’s Re2O Secures UAE Import Approval, Opening Door to Middle East

L&C Bio, a company specializing in regenerative medicine utilizing human tissue, has secured import approval for its product, Re2O, in the United Arab Emirates (UAE). This achievement positions the company for expansion into the Middle East, complementing its existing reach in Asia, South America, and North America. The UAE’s well-established medical tourism industry, evidenced by over 691,000 international medical tourists in Dubai alone in 2025, is expected to bolster the product's reception.

L&C Bio plans to leverage this approval by establishing a robust network of medical professionals and expanding its sales base through collaborations with local entities. The company's flagship product, Re2O, is derived from human acellular dermal matrix (hADM), processed into fine particles that maintain the structural integrity of skin tissue.

Recognizing the surging international demand, L&C Bio intends to double its Re2O production capacity to over 150,000 units monthly by year-end, with a new manufacturing facility in Dongtan planned for the future. Earlier this year, on Oct. 12, L&C Bio sealed an exclusive supply agreement with a U.S.-based partner, committing to meet substantial Re2O demand in the U.S. market starting in 2027, with the possibility of further structural expansion depending on market conditions.

Success in overseas markets hinges on local professional adoption and a stable distribution network, and L&C Bio is strategically positioning itself for entry into the U.S. market post-approval by focusing on medical professional training and academic activities. The company's UAE import approval is seen as a crucial step towards realizing these expansion goals.